The Daily Toke

April 30, 2026

Republican congressional leaders are moving to block federal cannabis rescheduling even as the Trump administration advances the reform, creating an unusual split within the party on drug policy. The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies released a funding bill this week containing Section 591, which would prohibit the use of any federal funds to reschedule marijuana or remove it from the Controlled Substances Act schedules. The provision directly contradicts the Department of Justice's April 23 announcement that state-licensed medical marijuana and FDA-approved cannabis products immediately moved to Schedule III, with a broader administrative hearing scheduled for this summer to consider fuller rescheduling.

This marks the latest iteration of a legislative pattern stretching back years. The appropriations committee has advanced similar language in past budgets during federal rescheduling debates, though none have previously made it into law. What's changed now is the backdrop: the Trump administration is actively moving forward with the reform despite congressional obstruction, creating genuine tension between executive action and legislative resistance. The committee, which takes up the bill Thursday, has framed the measure as a defense of federal drug scheduling authority, even as the sitting administration redefines that authority itself.

💰 MONEY MOVES The rescheduling announcement has already begun opening doors for the cannabis industry's most fundamental constraint: access to capital. The DEA is now accepting applications from state-licensed medical cannabis businesses seeking federal protections and tax breaks under the new Schedule III status. Major banks and investors, previously skittish about federally illegal activity, face meaningfully reduced legal risk when serving registered medical operators, though the change is not a clean bill of health—Schedule III substances remain controlled, and banking them still carries some federal liability under money laundering statutes. Still, the shift from Schedule I to Schedule III transforms the legal calculus from criminal exposure to manageable regulatory compliance.

The public record shows broad support for even moving beyond Schedule III. A Johns Hopkins and UC San Diego study analyzing 42,913 public comments submitted during the 2024 DEA rescheduling proposal found that 63.5% of commenters supported even more reform—full descheduling—while 28.9% supported Schedule III as proposed, and only 6.7% opposed any change. Supporters cited therapeutic benefits (56.7%), economic impacts on state revenues and the cannabis industry (27.8%), and the need for clearer federal regulation (24.4%). Those pushing for full descheduling emphasized criminal justice reform, noting the disproportionate incarceration of marginalized communities under decades of Schedule I enforcement.

🚀 THIS IS COOL The rescheduling move is already opening research pathways frozen for over fifty years. When the DOJ moved medical marijuana to Schedule III, it dismantled the primary bureaucratic barrier to clinical study—researchers can now access federally funded grants and conduct rigorous trials on cannabis's therapeutic and adverse effects with far less friction. This matters because decades of Schedule I restrictions have created a genuine knowledge gap: we know more about emerging cannabinoids than we know about cannabis itself as a whole plant medicine.

🤔 THINK ABOUT IT The congressional block attempt raises a basic question about federal drug policy: if state-licensed medical cannabis operators now hold DEA registrations and operate under federal oversight, and if public input runs 92.4% in favor of Schedule III or greater reform, on what grounds do lawmakers justify blocking the administration's own regulatory direction? The funding language suggests a desire to preserve scheduling authority itself, independent of current evidence or public preference—a position that, by definition, assumes the apparatus matters more than the outcomes it's designed to protect.

April 30, 2026

# Cannabis Business Briefing: April 30, 2026

Federal regulators are accelerating cannabis normalization even as some Republicans attempt to block the shift. The Drug Enforcement Administration launched its "Medical Marijuana Dispensary Registration Portal" on Wednesday, allowing state-licensed medical cannabis businesses to apply for federal protections and tax benefits under the Trump administration's recent rescheduling decision. The move follows the Department of Justice's announcement that marijuana is transitioning from Schedule I to Schedule III of the Controlled Substances Act, with state-licensed medical products and FDA-approved cannabis drugs immediately shifted to Schedule III status. 💰 MONEY MOVES Businesses that successfully register can now access legal protections and tax advantages previously unavailable to them, marking a significant market shift for the estimated thousands of state-licensed dispensaries operating across America's medical cannabis markets.

The DEA's new application process asks dispensaries detailed questions about their operational security, inventory management, storage protocols, and staff backgrounds—standard regulatory compliance for Schedule III substances. Applicants must document their state licenses, describe their security infrastructure including vaults and alarm systems, and disclose any prior involvement with controlled substance distribution. The portal also asks whether businesses handle recreational marijuana, even though only medical products have been rescheduled so far. An expedited administrative hearing process is set to begin June 29 to consider broader rescheduling of all cannabis from Schedule I to Schedule III, potentially opening the market further.

Yet movement forward faces Congressional resistance. The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies is advancing a bill Thursday that contains provisions designed to block federal marijuana rescheduling—even as the Trump administration pushes the reform forward. Rep. Alexandria Ocasio-Cortez told Marijuana Moment she supports the administration's rescheduling move, though she noted it "doesn't quite make all the wrongs right" by leaving behind people "whose lives were destroyed by the war on drugs." Meanwhile, South Carolina's Governor Henry McMaster's office indicated state law will "require the State to mirror the new federal order," potentially triggering automatic medical cannabis access for patients under existing state statutes that were written to activate upon federal rescheduling.

The House Appropriations Committee also approved a spending bill with an attached report expressing concerns about unregulated cannabis product manufacturers making false health claims. 🚀 THIS IS COOL The committee specifically called on the FDA to increase enforcement against cannabis products marketed with unlawful claims that they can treat serious illnesses like COVID-19 and cancer, while separately encouraging federal research into the therapeutic benefits of psychedelics. The report acknowledges that cannabis-derived products may be contaminated with harmful substances when manufactured without regulatory oversight, but stops short of suggesting prohibition—instead advocating for proper FDA compliance and scientific evaluation of legitimate therapeutic claims.

The regulatory split reflects broader market dynamics: legitimate medical cannabis businesses are moving into the regulated federal system, while unscrupulous manufacturers making false health claims face increased enforcement. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans annually and prescription opioids kill over 16,000 per year, yet both remain Schedule I's alternatives while cannabis—with zero recorded overdose deaths in human history—is only now being rescheduled. The tension between Congressional resistance and executive action suggests cannabis normalization will advance through regulation rather than outright prohibition, with state-licensed medical businesses positioned to benefit significantly from federal legal status.

April 30, 2026

Congress has quietly enacted the most significant federal hemp policy shift since 2018, tucking a near-total ban on intoxicating hemp products into a government funding bill signed by President Trump in November 2025. The legislation, part of H.R. 5371, rewrites federal hemp law by replacing the 2018 Farm Bill's 0.3% delta-9 THC standard with a "total THC" measurement that counts all THC forms—including THCa and converted cannabinoids—with a staggeringly restrictive 0.4 milligram cap per finished product container. For context: a single hemp gummy typically contains 2.5 to 10 milligrams of THC, meaning 💰 MONEY MOVES the ban will effectively eliminate 95% of the $28 billion hemp retail market when it takes effect in November 2026. Jonathan Miller, general counsel of the U.S. Hemp Roundtable, described it plainly: "In effect, this is a total, all out, complete ban on hemp products in the United States."

The one-year transition period provides limited runway for an industry that employs over 300,000 people across farming, extraction, manufacturing, logistics, and retail. The law also bans synthetically converted cannabinoids—delta-8, delta-10, HHC, THCP—that flourished in the legal gray market after 2018, and tightens restrictions on intermediate materials and work-in-process extracts moving through supply chains. What remains technically legal are industrial hemp products like rope, textiles, and grain; pure CBD isolate with no more than 0.4 mg total THC per container; and hemp as a crop itself. But for the companies and workers who scaled operations around intoxicating hemp products in the past seven years, the distinction offers cold comfort.

The enforcement question looms largest. The FDA has publicly stated since before 2018 that adding THC to food and beverage products violates federal law—yet enforcement has been selective, targeting brands making therapeutic claims, marketing to children, or copying popular food brands. 🤔 THINK ABOUT IT Federal regulators have decades of documented opportunity to shut down the hemp THC market and chose not to, yet now Congress is legislating what the executive branch could have enforced all along. Whether the federal government will actually prosecute violations under the new cap, or whether—as with marijuana prosecutions—enforcement falls to states, remains genuinely uncertain. Some states are already moving independently: Texas implemented its own total THC ban effective March 31, 2026, ahead of the federal deadline, while others like Arkansas, Idaho, Kansas, Louisiana, Oklahoma, Oregon, Rhode Island, Utah, and Vermont have enacted their own restrictions targeting smokable hemp and THCA products.

Several states are actively challenging the federal framework through legislative channels, and industry groups are scrambling to pivot. Some companies are shifting focus toward industrial hemp applications—bioplastics, hempcrete, protein products—though profit margins in industrial hemp are substantially lower than retail cannabinoid products. Others are building inventory before November 2026, banking on legal challenges or legislative reversals. The window for purchasing legal hemp-derived THC products online is finite, and retailers are openly discussing the looming deadline with consumers who rely on these products for pain management, anxiety, sleep, and PTSD symptoms. Veterans' advocates have noted particular concern: many veterans use legal intoxicating hemp products as alternatives to opioids and pharmaceutical drugs, and the ban narrows their options during a critical period when overdose deaths from prescription opioids remain above 16,000 annually in the United States.

💰 MONEY MOVES The ripple effects extend to land use, contracted acreage, and farm equipment financing. Farmers who invested in hemp cultivation infrastructure after 2018 now face canceled or restructured contracts, and regional economies dependent on hemp farming—particularly in states like Colorado, Oregon, and Kentucky—are bracing for contraction. Michael Gorenstein, CEO of Cronos Group, warned of cascading financial losses across farming, extraction, and retail sectors. The legislation itself makes no accommodation for workers, farmers, or small businesses caught between the old definition and the new one. What the law does clarify is that it does not criminalize hemp cultivation, does not affect state medical or recreational marijuana programs, and does not address cannabis from a scheduling perspective—only how federal law defines "legal hemp" for commercial purposes. Whether that distinction matters to farmers holding contracts for crops that will be illegal to sell in twelve months remains to be seen.

April 30, 2026

Scientists are pulling back the curtain on medical cannabis, and the picture is more complicated than either cheerleaders or skeptics have suggested. A major review published in December found little evidence that THC and CBD work as medicine for most conditions—a sobering assessment that contradicts years of patient testimonials and pushes the scientific community toward rigorous clinical trials rather than assumptions. UCHealth and other research institutions are now running formal trials to answer the question that should have been settled decades ago: Does marijuana actually work as medicine? The gap between what patients report and what controlled studies show suggests we've been operating on hope and anecdote when we should have been collecting data.

🚀 THIS IS COOL That said, there are genuine bright spots in the research. A scientific review published in January found that CBD shows "substantial promise" in combating tumors from cancer—a result worth taking seriously and building on with larger trials. This is the kind of finding that justifies continued research, not prohibition. The same research also identified hidden risks worth monitoring, which is exactly what responsible science looks like: acknowledging both potential benefits and genuine concerns rather than picking a narrative and defending it.

The core problem isn't that cannabis is dangerous—it isn't—but that we've spent decades treating it as Schedule I (no accepted medical use, high abuse potential) while running almost no clinical trials to test that classification. Over 50 years of prohibition has created a vacuum of evidence, not a foundation of safety concerns. Veterans with PTSD, patients with chronic pain, and people managing anxiety have reported real relief from THC products, yet the federal classification forces them to work around a legal fiction rather than within a medical framework. When the science finally catches up, we'll likely find that cannabis is useful for some conditions and not others—like every other medicine ever studied.

🤔 THINK ABOUT IT Consider the absurdity: alcohol kills approximately 95,000 Americans per year. Prescription opioids kill over 16,000 annually. Cannabis has never caused a single recorded overdose death in human history. Yet one is legal, one is loosely regulated, and one remains Schedule I. The clinical trials happening now aren't about discovering whether cannabis is safe—that question was answered long ago by simple math. They're about answering which specific conditions it actually treats, and at what doses. That's the conversation science should have started in the 1970s.

The real story here is momentum toward honest research. Britannica is documenting the pros and cons without ideology. UCHealth is running the trials that should have been standard practice since Nixon's administration. Newswise is reporting that evidence is lacking for most conditions—which is actually good news, because it means we can stop making claims we can't support and start building evidence we can. The patients, the veterans, and the broader public deserve a medical system based on data rather than a drug war based on bureaucratic inertia. That shift is finally beginning to happen.

April 30, 2026

Trump Administration May Reconsider Federal Prosecutions of Marijuana Users Facing Gun Charges, Even as DOJ Defends Ban Before Supreme Court

Acting Attorney General Todd Blanche said Wednesday that the Trump administration is actively reconsidering whether to prosecute marijuana users under federal law 922(g)(3), which bars cannabis consumers from possessing firearms. The statement marks a potential shift in enforcement strategy, though Blanche emphasized the change would happen "case by case" rather than through a sudden policy reversal. "Yes, of course we are" reconsidering the stance, Blanche told reporters during an ATF briefing on new firearms regulations. "Every case is different. The facts leading up to where we are in a litigation is different." The remarks came as the administration released 34 new notices of final and proposed rulemaking on gun policies, with at least one potentially affecting how the existing ban on gun purchases by cannabis users is enforced, though the full text remains unreleased.

The timing creates an interesting tension: just last month, the Trump DOJ argued before the U.S. Supreme Court that the federal ban on cannabis consumers owning guns is constitutional under the Second Amendment. Solicitor General D. John Sauer even sent the justices a letter arguing that marijuana's recent federal rescheduling should not impact their decision in the case. Blanche acknowledged this contradiction exists but framed it as practical reality—the administration has recent Supreme Court filings and pending cases across multiple court levels that cannot be instantly unwound. "It's not as smooth as a single day, but it's also not as clunky as taking forever," he said. Still, the stated reconsideration suggests potential future action that could reshape how federal firearms law applies to the estimated 24 million adult cannabis users in America.

Meanwhile, the Senate Veterans' Affairs Committee heard testimony Wednesday on a bipartisan bill to establish a new Department of Veterans Affairs office dedicated to psychedelics research and treatment. 🚀 THIS IS COOL The Veterans Health Administration Novel Therapeutics Preparedness Act, led by Republican Tim Sheehy of Montana and cosponsored by Democrats Tammy Duckworth and Ruben Gallego, would fund research into psilocybin, ibogaine, and MDMA as treatments for PTSD and other serious mental health conditions affecting veterans. Gallego noted that many veterans are currently traveling to Mexico and other unregulated markets to access psychedelic therapies because domestic options remain limited. "We certainly want to make sure veterans have safe access to all therapies," Gallego said, arguing that the government has "a responsibility to deliver the best possible care to our veterans." A Democratic senator at the hearing said the Trump administration has been "better" on psychedelics reform than the Biden administration was.

The VA testified it does not support creating a new dedicated office, arguing that an existing Integrated Project Team already handles psychedelics-related functions. This bureaucratic resistance contrasts with growing bipartisan recognition that psychedelic-assisted therapies offer genuine clinical hope where traditional treatments have failed—a position increasingly supported by peer-reviewed research and veteran advocacy groups.

Separately, the House Appropriations Committee on Wednesday approved a spending bill with language demanding that the FDA crack down on cannabis product manufacturers making unlawful health claims. 💰 MONEY MOVES The report expresses concern about a "proliferation" of cannabis-derived products marketed with false or unsubstantiated claims that they treat serious illnesses including COVID-19 and cancer. The committee called on the FDA to "take enforcement action against the manufacturers of any cannabis products marketed with unlawful therapeutic claims to preserve the integrity of the drug development and approval processes." The same report also expressed separate support for continued research into psychedelics' therapeutic potential, creating an interesting policy moment where Congress simultaneously wants stricter enforcement against misleading cannabis marketing while encouraging legitimate research into other plant-based therapies.

🤔 THINK ABOUT IT Federal law currently classifies cannabis as Schedule I—meaning "no accepted medical use"—while simultaneously cracking down on companies making medical claims about it, and while also funding research into psychedelics as legitimate medicine. The contradiction suggests less about cannabis science and more about how policy categories lag behind the evidence. Veterans can't access federally-supported psychedelics clinics yet, but they can be prosecuted for possessing guns if they use legal state cannabis. The pieces are shifting, but the framework remains tangled.